Released on = February 26, 2007, 8:35 am

Press Release Author = La Merie Business Intelligence

Industry = Biotech

Press Release Summary = Sales of the major cancer antibodies grew by 57 % to US$
10.6 bln in 2006. Cancer antibodies are challenging the still no. 1 selling class of
erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4 %),
and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25 %).

Press Release Body = BARCELONA, Spain | Feb 26, 2007 | The Business Intelligence
firm La Merie S.L. reported today that the major cancer antibodies Rituxan,
Herceptin, Avastin and Erbitux represent the no. 2 class of top selling biologics
with the hightest growth rate of 57 % and combined 2006 sales of US$ 10.6 bln. In
contrast, the class of erythropoietin products still had the highest sales in 2006
with US$ 11.9 bln, buth with the lowest growth rate (6.7 %) of all 12 classes of
recombinant biologics (excluding vaccines) with sales higher than US$ 1 bln. The
single biologic product with highest sales in 2006 was the anti-TNF drug Enbrel (US$
4.5 bln), but Humira had the highest growth rate (+ 46 %) among the anti-TNF
antibodies which are the no. 3 class with combined 2006 sales of US$ 10.3 bln. The
increasing conversion of insulin to insulin analogs explains the growth rate of 24 %
in the class of insulin products with sales of US$ 9 bln in 2006. Recent new product
launches contributed to the 28 % growth of enzyme replacement therapies to 2006
sales of US$ 1.7 bln. Recombinant coagulation factors posted 2006 sales of US$ 4.7
bln (+ 17 %). Total sales of the 12 top selling biologic products with sales per
class over US$ 1 bln grew by 20 % from US$ 53 bln to US$ 63.8 bln in 2006. These
results and more were found in a search conducted by La Merie Business Intelligence
and published in a complimentary report on February 26, 2007. The document entitled
"TOP 20 Biologics 2006" can be acquired as a free download at La Merie's News Center
and Online Store PipelineReview.com (www.pipelinereview.com).

The "TOP 20 Biologics 2006" report presents in tabular format 2006 sales figures of
the TOP 20 selling single biologic products, of the 12 top-selling classes of
recombinant biologicals, i.e. proteins and antibodies (excluding vaccines and
peptides), and in detail the sales figures of the individual products of the 12 top
selling classes of biologics. In addition, information is provided on brand and
generic names, target, class of compound, originator and licensee companies, product
category and major indications. Growth rates of the ten best selling classes of
biological products are graphically compared and a table with sales figures of
selected individual biologics with sales of less than US$ 1 bln is provided. All
information is fully referenced by a hyperlink leading to the original source of
information. References can be found for reports of La Merie's Competitor Analysis
series related to the top selling classes of biologics.

About La Merie

La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high
quality R&D information to the biopharmaceutical industry. La Merie offers
individual consultancy services and publishes reports and periodicals. For more
information visit www.lamerie.com.

About PipelineReview.com

PipelineReview.com is the News Center and Online Store of La Merie Business
Intelligence focused on Research and Development in the Biopharmaceutical Industry.
Visitors of PipelineReview.com will find R&D relevant press releases and can receive
selected R&D news from one or more of the site's News Channels. A free R&D
Newletter conveniently brings via e-mail a daily selection of the most interesting
news from biopharmaceutical R&D. For more information visit www.pipelinereview.com.

SOURCE: La Merie Business Intelligence


Web Site = http://www.pipelinereview.com

Contact Details = La Merie Business Intelligence
C/ Caspe, 33B, 4º, 2ª
E-08010 Barcelona
Tel +34-93-342 91 97
Fax +34-93-342 91 98
e-mail: jorge.marquez@lamerie.com
Website: http://www.lamerie.com
Online Store: www.pipelinereview.com